Spots Global Cancer Trial Database for mismatch repair deficiency

Every month we try and update this database with for mismatch repair deficiency cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	NCT03452774	Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic...	Clinical Trial ...	-	Massive Bio, Inc.
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer	NCT06215677	Colon Cancer Mismatch Repair... Immunotherapy	Camrelizumab	18 Years - 75 Years	Peking Union Medical College Hospital
Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome	NCT05257057	Lynch Syndrome Endometrial Can... Endometrial Hyp... Mismatch Repair... Microsatellite ...	Immunohistochem...	18 Years - 99 Years	WellSpan Health
Anti-PD-1 +/- RT for MSI-H Solid Tumors	NCT04001101	Microsatellite ... Mismatch Repair... Colorectal Canc...	RT and Anti-PD-... Anti-PD-1	18 Years - 100 Years	University of Colorado, Denver
Prostate Cancer Genetic Risk Evaluation and Screening Study	NCT05129605	Prostatic Neopl... Prostate Cancer BRCA2 Mutation BRCA1 Mutation ATM Gene Mutati... MMR Mutation Lynch Syndrome Genetic Predisp...	Prostate cancer...	35 Years - 74 Years	Massachusetts General Hospital
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors	NCT03053466	Solid Tumor Microsatellite ... Mismatch Repair... Cancer of Unkno...	APL-501	18 Years -	Apollomics (Australia) Pty. Ltd.
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers	NCT03935893	Gastric Cancer Colorectal Canc... Pancreatic Canc... Sarcoma Mesothelioma Neuroendocrine ... Squamous Cell C... Merkel Cell Car... Mismatch Repair... Microsatellite ...	Tumor Infiltrat... Fludarabine + C...	18 Years - 75 Years	University of Pittsburgh
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer	NCT02983578	Advanced Colore... Advanced Lung N... Lung Non-Small ... Mismatch Repair... Refractory Colo... Refractory Lung... Refractory Panc... Stage II Pancre... Stage III Color... Stage III Lung ... Stage III Pancr... Stage IIIA Colo... Stage IIIA Lung... Stage IIIB Colo... Stage IIIB Lung... Stage IIIC Colo... Stage IIIC Lung... Stage IV Colore... Stage IV Lung C... Stage IV Pancre... Stage IVA Color... Stage IVA Lung ... Stage IVB Color... Stage IVB Lung ... Stage IVC Color...	Danvatirsen Durvalumab	18 Years -	M.D. Anderson Cancer Center
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival	NCT04482608	Colorectal Canc... Mismatch Repair... Microsatellite ...		18 Years - 80 Years	Sun Yat-sen University
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	NCT03228667	Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc...	N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu...	18 Years -	ImmunityBio, Inc.
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors	NCT03053466	Solid Tumor Microsatellite ... Mismatch Repair... Cancer of Unkno...	APL-501	18 Years -	Apollomics (Australia) Pty. Ltd.
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types	NCT06034860	Non Small Cell ... Hepatocellular ... Melanoma Renal Cell Carc... Microsatellite ... Mismatch Repair... Mesothelioma Esophageal Squa... Squamous Cell C... Urothelial Carc... Cervical Cancer	MT-8421 Nivolumab	18 Years -	Molecular Templates, Inc.
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy	NCT06362369	Advanced Cancer Advanced Solid ... Melanoma Metastasis Pleural Mesothe... Renal Cell Carc... MSI-High Mismatch Repair... Colorectal Canc... Hepatocellular ... Hepatocellular ... Renal Cell Canc... Kidney Cancer Skin Cancer Non Small Cell ... NSCLC Anaplastic Lymp... ALK Genomic Tum...	Alintegimod Ipilimumab Nivolumab	18 Years -	7 Hills Pharma, LLC
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer	NCT04906382	Lynch Syndrome Recurrent Endom... Recurrent Endom... Recurrent Uteri... Mismatch Repair... Recurrent Endom... Metastatic Endo...	Biopsy Carboplatin Paclitaxel Tislelizumab	18 Years -	Ohio State University Comprehensive Cancer Center
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors	NCT05098132	Advanced Solid ... Non Small Cell ... Head and Neck S... Malignant Melan... Renal Cell Carc... Cervical Cancer Microsatellite ... Gastric Cancer GastroEsophagea... Urothelial Carc... Mismatch Repair...	STK-012 Pembrolizumab	18 Years -	Synthekine
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	NCT03228667	Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc...	N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu...	18 Years -	ImmunityBio, Inc.
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation	NCT04104893	Metastatic Cast...	Pembrolizumab	18 Years -	VA Office of Research and Development
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation	NCT04104893	Metastatic Cast...	Pembrolizumab	18 Years -	VA Office of Research and Development
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)	NCT04439214	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas...	Nivolumab	18 Years -	National Cancer Institute (NCI)
Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome	NCT05257057	Lynch Syndrome Endometrial Can... Endometrial Hyp... Mismatch Repair... Microsatellite ...	Immunohistochem...	18 Years - 99 Years	WellSpan Health
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	NCT03652077	Cervical Cancer Gastric Cancer Stomach Cancer Gastroesophagea... Esophageal Canc... Hepatocellular ... Melanoma Uveal Melanoma Merkel Cell Car... Mesothelioma MSI Non-small Cell ... NSCLC Ovarian Cancer Squamous Cell C... Small Cell Lung... Renal Cell Carc... RCC Triple-negative... Urothelial Carc... Mismatch Repair...	INCAGN02390	18 Years -	Incyte Corporation
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab	NCT03767348	Cancer Melanoma (Skin) Mismatch Repair... Microsatellite ... Non-melanoma Sk... Cutaneous Melan... NSCLC	RP1 nivolumab	18 Years -	Replimune Inc.
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors	NCT03228667	Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc...	N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu...	18 Years -	ImmunityBio, Inc.
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)	NCT04439214	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas...	Nivolumab	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: